文献速递肝病消化道肿瘤与早癌

肝细胞癌免疫检查点抑制剂临床开发的挑战与机遇

Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2019-01-01

本文综述了免疫检查点抑制剂(ICPIs)在晚期肝细胞癌中逆转免疫耗竭的有效性,截至2018年5月已有超过50项免疫治疗临床试验注册。文章讨论了支持ICPIs在肝细胞癌各分期开发的生物学基础,重点在于根据巴塞罗那临床肝癌(BCLC)分期合理定位ICPIs,并强调转化研究应指导治疗药物和联合策略的优先排序。

要点

  • 免疫检查点抑制剂可逆转免疫耗竭,对晚期肝细胞癌有效。
  • 截至2018年5月,超过50项免疫治疗临床试验注册用于肝细胞癌。
  • 转化研究应基于机制和临床依据指导药物及联合策略的优先排序。

核心结论

  • 免疫检查点抑制剂通过逆转免疫耗竭在晚期肝细胞癌中显示有效,但其临床开发在肝细胞癌患者中特别具有挑战性。

研究设计与样本

  • 本综述讨论了支持免疫检查点抑制剂在肝细胞癌各进展阶段开发的生物学基础,重点在于根据巴塞罗那临床肝癌(BCLC)分期合理定位免疫检查点抑制剂。

主要发现

  • 截至2018年5月,已有超过50项免疫治疗药物临床试验注册用于肝细胞癌。
  • 肝细胞癌患者具有独特特征,影响免疫调节治疗的安全性和有效性。

临床怎么用

  • 转化研究应指导基于可靠机制和临床依据的治疗药物及联合策略的优先排序,以最大可能使患者获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

After a decade of stagnation in drug development, therapeutic reversal of immune-exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in advanced hepatocellular carcinoma (HCC). The clinical development of novel ICPIs continues at a rapid pace, with more than 50 clinical trials of immunotherapeutic agents registered as of May 2018 for this indication. The development of ICPI is particularly challenging in patients with HCC, a population with unique features which impact on safety and efficacy of immune-modulating therapies. In this review, we discuss the biological foundations supporting the development of ICPIs across the advancing stages of HCC, focusing on the rational positioning of ICPIs across the various Barcelona-Clinic Liver Cancer (BCLC) stages of the disease. Translational studies should guide adequate prioritization of those therapeutic agents and combination strategies which are most likely to achieve patient benefit based on solid mechanistic and clinical justifications.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Flynn MJ, Sayed AA, Sharma R, et al. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology. 2019. PMID: 30382576. doi:10.1002/hep.30337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。